Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial.

Loading...
Thumbnail Image

Date

2012-01

Journal Title

Journal ISSN

Volume Title

Repository Usage Stats

81
views
40
downloads

Citation Stats

Abstract

BACKGROUND: HER-2/neu-targeted therapy has been successfully used in advanced gastric cancer, but the role of HER-2/neu in the prognosis of gastric cancer is not yet clear. In this study, we investigated the correlation between HER-2/neu expression and amplification as well as their association with clinic outcomes in patients with curatively resected gastric cancer. METHODS: We constructed tissue microarray blocks containing >70% of gastric cancer tissue and matched adjacent normal gastric tissue for 227 patients. Expression of the HER-2/neu protein in these specimens was analyzed using immunohistochemical staining. Amplification of HER-2/neu was also analyzed for the same samples using fluorescence in situ hybridization. Data on clinicopathological features and relevant prognostic factors in these patients were analyzed. RESULTS: Of the 227 gastric cancer samples, 11.89% were positive for HER-2/neu overexpression/amplification under the new scoring system. HER-2/neu overexpression/amplification was closely correlated to the Lauren type, degree of differentiation, tumor size and lymph node metastasis. HER-2/neu overexpression/amplification predicted poor survival in univariate analysis but not in a Cox proportional hazards model. CONCLUSION: HER-2/neu overexpression/amplification was not an independent predictor for survival in patients with curatively resected gastric cancer.

Department

Description

Provenance

Citation

Published Version (Please cite this version)

10.1186/1477-7819-10-274

Publication Info

Zhou, Fei, Ning Li, Weihua Jiang, Zhaolai Hua, Lin Xia, Qingyi Wei and Liwei Wang (2012). Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial. World journal of surgical oncology, 10(1). p. 274. 10.1186/1477-7819-10-274 Retrieved from https://hdl.handle.net/10161/17992.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.


Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.